Stephan W. Morris, MD Chief Medical Officer
Marked improvements in cancer management have been realized during my nearly 40-year career as a clinical and molecular oncologist, and I am pleased to have contributed to some of those improvements such as the development of Anaplastic Lymphoma Kinase (ALK) diagnostics and therapeutics. Like ALK-targeted drugs, which have revolutionized the treatment of certain types of cancers, the drug candidates being developed by RaCRx have the potential to provide a paradigm shift in our treatment of a variety of malignancies. Betsy Fisher
Chief Operating Officer
When I decided to join RaCR, I knew I was becoming part of a dynamic company that would bring innovative solutions to cancer treatment. Having recently experienced the pain and feeling of powerlessness watching loved ones lose their battle with cancer, I’ve become motivated more than ever to be integrally involved in bringing new treatments and potential cures for cancer. Kent Murphy
Chief Executive Officer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam id fermentum sapien. Nulla et turpis sit amet odio venenatis ultricies ut vel sem.
